Ua hoʻolaha ʻo Morningside Ventures i kēia lā i ka hoʻokuʻu ʻana o Adiso Therapeutics, kahi hui biotechnology o ke kaiapuni e holomua ana i kahi pipeline o nā therapeutics novel e kuhikuhi ana i nā maʻi ʻeha. Ua hoʻolako kālā ʻo Morningside i nā hoʻolālā hoʻomohala Adiso a hiki i kēia lā, me nā hoʻolālā e kākoʻo hou i ka ulu wikiwiki o ka ʻoihana e neʻe nei i mua.
Ke hoʻomau nei ʻo Adiso i kahi pipeline hou o nā molekole liʻiliʻi me nā hana hou o ka hana a me nā huahana biotherapeutic ola hoʻokahi (SS-LBP), e ʻimi ana i nā hōʻailona o ka ulcerative colitis (UC), a me ka maʻi C. difficile (CDI). Ma waho aʻe o nā papahana ʻelua Phase 1 (UC & CDI) a me kahi papahana Phase 2 (UC), ke kūkulu nei ʻo Adiso i kahi papahana inflammasome novel i ka pae ʻike e ʻimi mua ʻia ana i ka ʻeha hanu, me nā wahi lapaʻau e hiki mai ana e alualu.
Aia ka hui he 25 mau limahana ma mua, ma lalo o ka umbrella Morningside, ua wehe kūleʻa ʻekolu Investigational New Drug (INDs) a ua waiho i nā patent he nui a me ka loaʻa ʻana o ka US FDA Fast Track Designation, a hiki i ka hoʻokumu ʻana o Adiso. E hana ʻo Adiso ma lalo o ke alakaʻi ʻana o ka Luna Nui i koho ʻia, ʻo Scott Megaffin. Loaʻa iā Mr. Megaffin ma luna o 30 mau makahiki o ka ʻoihana ʻoihana a me kahi moʻolelo kūleʻa i nā kūlana alakaʻi kiʻekiʻe ma Bristol-Myers Squibb, Pfizer, Schering-Plough, Adolor, Onconova, a me Churchill. ʻO ka mea hou loa, ua lawelawe ʻo Mr. Megaffin ma ke ʻano he Luna Nui o Adastra Pharmaceuticals, kahi hui hoʻomohala oncology clinical-stage development, kahi āna i alakaʻi ai i ka hui i kahi kālepa kūleʻa me Cothera Bioscience i ʻOkakopa 2021.
"Ke kū nei nā pono olakino koʻikoʻi no nā lāʻau lapaʻau hou e kuhikuhi ana i ka biology kumu o nā maʻi inflammatory me ka ʻole o ka hoʻoulu ʻana i ka immunosuppression systemic," wahi a Jason Dinges, Morningside Technology Advisory a me Adiso Board Member. "Ke holo nei ʻo Adiso ma waho o ka ʻīpuka me ʻekolu mau papahana lapaʻau maikaʻi loa no ka mālama ʻana i ka ulcerative colitis a me ka pale ʻana i ka CDI hou. Ke manaʻoʻiʻo nei mākou ma lalo o ke alakaʻi ʻana a Scott a me kahi hui akamai o nā mea hoʻomohala lāʻau lapaʻau, ua mākaukau ʻo Adiso no ka kūleʻa.
"Ma Adiso ke hoʻopaʻa nei mākou i nā maʻi inflammatory me nā ʻano hana like ʻole a me kahi ala wiwo ʻole. Manaʻo mākou i kahi ʻoiaʻiʻo hou no nā maʻi, e hoʻohana ana i nā holomua ʻike ʻia o nā therapeutic inflammatory e hoʻohiki nei e hoʻoponopono hou i ka ʻōnaehana pale o ka mea hoʻokipa, i ʻole e hoʻoulu ʻia ka maʻi inflammatory lalo a ʻaʻole hoʻi i lilo ka mea maʻi i immunocompromised, "wahi a Scott Megaffin, Luna Nui o Adiso Therapeutics . "Hoʻohanohano wau i ke alakaʻi ʻana i kahi hui kūʻokoʻa, papa honua, a hoʻolaʻa ʻia ma Adiso i ka hoʻomohala ʻana i kēia mau lāʻau lapaʻau kūikawā i hoʻolālā ʻia e kāpae pono i ka dysregulation i hana ʻia e ka mumū."
Ua hui pū ʻo Mustafa A. Noor, MD, FACP i ka hui alakaʻi Adiso. Lawe ʻo Kauka Noor i ke kūlana o ka Luna Lapaʻau Nui, e lawe mai ana ma mua o 20 mau makahiki o ka hoʻomohala ʻana i ka lāʻau lapaʻau ma waena o nā wahi lapaʻau he nui i nā ʻoihana mua a i waena o ka pae honua me AMAG Pharmaceuticals, Akcea Therapeutics, Ipsen, Pfizer, Glaxo-Smith Kline , a me Bristol Myers Squibb.
"ʻO ka dysregulation inflammatory ke kikowaena o nā maʻi koʻikoʻi he nui a ʻo ka pōʻino e hoʻopilikia ai i ke olakino a me ka maikaʻi o nā maʻi. ʻAʻole lawa nā koho lapaʻau i kēia manawa no ka hoʻopau ʻana i ka piʻi ʻana o ka maʻi a hoʻomaikaʻi i ka maikaʻi o ke ola ma kahi ala palekana a kūpono hoʻi, "wahi a Kauka Noor, CMO o Adiso Therapeutics. "ʻO nā hiʻohiʻona kūʻokoʻa o ka waihona Adiso no ka mālama ʻana i nā maʻi inflammatory hiki ke lilo i mau lāʻau lapaʻau koʻikoʻi no nā maʻi. Ke kūkulu nei au i ka holomua preclinical a me ka hoʻomaka ʻana o nā noiʻi lapaʻau a hiki i kēia lā, ke kakali nei au i ke alakaʻi ʻana i nā pae aʻe o ka hoʻomohala ʻana i kā mākou kōpili me kahi hui loea o nā mea hoʻomohala lapaʻau.
